Deng, Yunfu
Ma, Guangzhi
Vallega, Karin A.
Wang, Dongsheng
Wang, Mingliang
Wang, Changwei
Wang, Shaomeng
Ramalingam, Suresh S.
Sun, Shi-Yong http://orcid.org/0000-0002-0117-8826
Article History
Received: 1 February 2022
Revised: 29 March 2022
Accepted: 7 April 2022
First Online: 21 April 2022
Change Date: 10 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41417-022-00479-w
Competing interests
: SSR is on consulting/advisory board for AstraZeneca, BMS, Merck, Roche, Tesaro and Amgen. The University of Michigan has filed a patent application on SHP2-D26 and its analogs. SW and MW are co-inventors of the patent application, which has been licensed by Roivant Sciences and Proteovant Therapeutics Inc. SW is a paid consultant to Roivant Sciences and Proteovant Therapeutics. The University of Michigan has received a research contract for which SW serves as the principal investigator. Other authors disclose that they have no potential conflicts of interest.